Oleoylethanolamide improves energy disposal in a cellular model of Alzheimer’s disease

References

• Atlante A, Amadoro G, Latina V, Valenti D. 2022. Therapeutic potential of targeting mitochondria for Alzheimer’s disease treatment. J Clin Med. 11(22):6742. doi: 10.3390/jcm11226742.
   PubMed Web of Science ®Google Scholar
• Bowen KJ, Kris-Etherton PM, Shearer GC, West SG, Reddivari L, Jones PJH. 2017. Oleic acid-derived oleoylethanolamide: a nutritional science perspective. Prog Lipid Res. 67:1–10. doi: 10.1016/j.plipres.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Breijyeh Z, Karaman R. 2020. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules (Basel, Switzerland). 25(24):5789. doi: 10.3390/molecules25245789.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP. 2010 Dec 1. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal. 13(11):1763–1811. doi: 10.1089/ars.2009.3074. Epub 2010 Aug 28. PMID: 20446769; PMCID: PMC2966482.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Giordano J, Signorile A, Laura Ontario M, Castorina S, De Pasquale C, Eckert G, Calabrese EJ. 2016. Major pathogenic mechanisms in vascular dementia: roles of cellular stress response and hormesis in neuroprotection. J Neurosci Res. 94(12):1588–1603. doi: 10.1002/jnr.23925.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Giuffrida Stella AM. 2007. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. 8(10):766–775. doi: 10.1038/nrn2214.
   PubMed Web of Science ®Google Scholar
• Corbett GT, Gonzalez FJ, Pahan K. 2015. Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci USA. 112(27):8445–8450. doi: 10.1073/pnas.1504890112.
   PubMed Web of Science ®Google Scholar
• Dieter F, Esselun C, Eckert GP. 2022. Redox Active α-Lipoic Acid Differentially Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer and Its Control Cells. Int J Mol. Sci. 23(16). doi: 10.3390/ijms23169186.
   PubMed Web of Science ®Google Scholar
• Esselun C, Dieter F, Sus N, Frank J, Eckert GP. 2022. Walnut oil reduces Aβ levels and increases neurite length in a cellular model of early Alzheimer disease. Nutrients. 14(9):1694. doi: 10.3390/nu14091694.
   PubMed Web of Science ®Google Scholar
• Friedland-Leuner K, Stockburger C, Denzer I, Eckert GP, Müller WE. 2014. Mitochondrial dysfunction: cause and consequence of Alzheimer’s disease. Prog Mol Biol Transl Sci. 127:183–210.
   PubMed Web of Science ®Google Scholar
• Gao L-B, Yu X-F, Chen Q, Zhou D. 2016. Alzheimer’s disease therapeutics: current and future therapies. Minerva Med. 107(2):108–113.
   PubMed Web of Science ®Google Scholar
• Giudetti AM, Vergara D, Longo S, Friuli M, Eramo B, Tacconi S, Fidaleo M, Dini L, Romano A, Gaetani S. 2021. Oleoylethanolamide reduces hepatic oxidative stress and endoplasmic reticulum stress in high-fat diet-fed rats. Antioxidants (Basel, Switzer-Land). 10(8):1289. doi: 10.3390/antiox10081289.
   PubMedGoogle Scholar
• Gonzalez-Aparicio R, Blanco E, Serrano A, Pavon FJ, Parsons LH, Maldonado R, Robledo P, Fernandez-Espejo E, de Fonseca FR. 2014. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental parkin-sonism. Int J Neuropsychopharmacol. 17(3):455–468. doi: 10.1017/S1461145713001259.
   PubMed Web of Science ®Google Scholar
• González-Aparicio R, Moratalla R. 2014. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 re-ceptor in a mouse model of Parkinson´s disease. Neurobiol Dis. 62:416–425. doi: 10.1016/j.nbd.2013.10.008.
   PubMed Web of Science ®Google Scholar
• Grewal R, Reutzel M, Dilberger B, Hein H, Zotzel J, Marx S, Tretzel J, Sarafeddinov A, Fuchs C, Eckert GP. 2020. Purified oleocanthal and ligstroside protect against mitochondrial dysfunction in models of early Alzheimer’s disease and brain ageing. Experimental Neurology. 328:113248. doi: 10.1016/j.expneurol.2020.113248.
   PubMed Web of Science ®Google Scholar
• Grimm A, Eckert A. 2017. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem. 143(4):418–431. doi: 10.1111/jnc.14037.
   PubMed Web of Science ®Google Scholar
• Guzmán M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D. 2004. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem. 279(27):27849–27854. doi: 10.1074/jbc.M404087200.
   PubMed Web of Science ®Google Scholar
• Hann SS, Zheng F, Zhao S. 2013. Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65. J Exp Clin Cancer Res. 32(1):43. doi: 10.1186/1756-9966-32-43.
   PubMedGoogle Scholar
• Kelley DE, He J, Menshikova EV, Ritov VB. 2002. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 51(10):2944–2950. doi: 10.2337/diabetes.51.10.2944.
   PubMed Web of Science ®Google Scholar
• Laleh P, Yaser K, Abolfazl B, Shahriar A, Mohammad AJ, Nazila F, Alireza O. 2018. Oleoylethanolamide increases the expression of PPAR-Α and reduces appetite and body weight in obese people: a clinical trial. Appetite. 128:44–49. doi: 10.1016/j.appet.2018.05.129.
   PubMed Web of Science ®Google Scholar
• Laleh P, Yaser K, Alireza O. 2019. Oleoylethanolamide: a novel pharmaceutical agent in the management of obesity-an updated review. J Cell Physiol. 234(6):7893–7902. doi: 10.1002/jcp.27913.
   PubMed Web of Science ®Google Scholar
• Lamichane S, Dahal Lamichane B, Kwon S-M. 2018. Pivotal roles of peroxisome proliferator-activated receptors (PPARs) and their signal cascade for cellular and whole-body energy homeostasis. Int J Mol Sci. 19(4):949. doi: 10.3390/ijms19040949.
   PubMed Web of Science ®Google Scholar
• Lin L, Mabou Tagne A, Squire EN, Lee H-L, Fotio Y, Ramirez J, Zheng M, Torrens A, Ahmed F, Ramos R, et al. 2022. Diet-induced obesity disrupts hista-mine-dependent oleoylethanolamide signaling in the mouse liver. Pharmacology. 107(7–8):423–432. doi: 10.1159/000524753.
   PubMed Web of Science ®Google Scholar
• Li G, Wang J, Ye J, Zhang Y, Zhang Y. 2015. PPARα protein expression was increased by four weeks of intermit-tent hypoxic training via AMPKα2-dependent manner in mouse skeletal muscle. PLoS One. 10(4):e0122593. doi: 10.1371/journal.pone.0122593.
   PubMed Web of Science ®Google Scholar
• Ma L, Guo X, Chen W. 2015. Inhibitory effects of oleoylethanolamide (OEA) on H₂O₂-induced human umbilical vein endothelial cell (HUVEC) injury and apolipoprotein E knockout (ApoE-/-) atherosclerotic mice. Int J Clin Exp Pathol. 8(6):6301–6311.
   PubMed Web of Science ®Google Scholar
• Onyango IG, Dennis J, Khan SM. 2016. Mitochondrial dysfunction in Alzheimer’s disease and the rationale for bioenergetics based therapies. Aging Dis. 7(2):201–214. doi: 10.14336/AD.2015.1007.
   PubMed Web of Science ®Google Scholar
• Orio L, Alen F, Pavón FJ, Serrano A, Oleoylethanolamide G-B-B. 2018. Neuroinflammation, and alcohol abuse. Front Mol Neurosci. 11:490. doi: 10.3389/fnmol.2018.00490.
   PubMed Web of Science ®Google Scholar
• Payahoo L, Khajebishak Y, Asghari Jafarabadi M, Ostadrahimi A. 2018. Oleoylethanolamide supplementation Re-duces inflammation and oxidative stress in obese people: a clinical trial. Adv Pharm Bull. 8(3):479–487. doi: 10.15171/apb.2018.056.
   PubMedGoogle Scholar
• Poornima MS, Sindhu G, Billu A, Sruthi CR, Nisha P, Gogoi P, Baishya, G., G Raghu, K. 2022. Pretreatment of hydroethanolic extract of dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1/p-LKB-1/AMPK, HMGCR & PPAR-α signaling pathways. J Ethnopharmacol. 292:115237. doi: 10.1016/j.jep.2022.115237.
   PubMed Web of Science ®Google Scholar
• Pugazhenthi S, Qin L, Reddy PH. 2017. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochim Biophys Acta Mol Bas Dis. 1863(5):1037–1045. doi: 10.1016/j.bbadis.2016.04.017.
   PubMed Web of Science ®Google Scholar
• Reutzel M, Grewal R, Joppe A, Eckert GP. 2022. Age-dependent alterations of cognition, mitochondrial function, and beta-amyloid deposition in a murine model of Alzheimer’s disease-A longitudinal study. Front Aging Neurosci. 14:875989. doi: 10.3389/fnagi.2022.875989.
   PubMed Web of Science ®Google Scholar
• Sabahi M, Ahmadi SA, Kazemi A, Mehrpooya M, Khazaei M, Ranjbar A, Mowla A. 2022. The effect of oleoylethanolamide (OEA) add-on treatment on inflammatory, oxidative stress, lipid, and biochemical parameters in the acute ischemic stroke patients: randomized double-blind placebo-controlled study. Oxid Med Cell Longev. 2022:1–11. doi: 10.1155/2022/5721167.
   Web of Science ®Google Scholar
• Silva MVF, Loures Cd MG, Alves LCV, de SL, Borges KBG, Carvalho Md G. 2019. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 26(1):33. doi: 10.1186/s12929-019-0524-y.
   PubMedGoogle Scholar
• Stockburger C, Gold VAM, Pallas T, Kolesova N, Miano D, Leuner K, et al. 2014. A cell model for the initial phase of sporadic Alzheimer’s disease. J Alzheimer’s Disease JAD. 42(2):395–411. doi: 10.3233/JAD-140381.
   PubMed Web of Science ®Google Scholar
• Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, Zhao Q-F, Li J-Q, Wang J, Yu J-T, et al. 2015. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 86(12):1299–1306. doi: 10.1136/jnnp-2015-310548.
   PubMed Web of Science ®Google Scholar
• Yen F-S, Wei J-C, Yip H-T, Hwu C-M, Diabetes H-C-C. 2022. Hypertension, and the risk of dementia. J Alzheimer’s Disease JAD. 89(1):323–333. doi: 10.3233/JAD-220207.
   PubMed Web of Science ®Google Scholar